E-Compared-CH: Comparative Effectiveness Research on Internet-based Depression Treatment - Swiss Trial

Not Applicable

Completed

• Conditions: Depressive Disorder, Major

• Registration Number: NCT02410616
• Lead Sponsor: University of Bern

Brief Summary

To compare the clinical and cost-effectiveness of blended Cognitive Behavioural Therapy (CBT) for adults with major depressive disorder (MDD) with treatment as usual (TAU) in Swiss patients in secondary care

Detailed Description

Background

Depression is a common mental disorder with a negative impact on mental well-being, quality of life, and social and work-related functioning both in the short and longer term. Additionally, depression is associated with increased morbidity, mortality, health care utilization and health care costs. On a population level, depression is one of the most costly diseases. The economic costs of depression were estimated at €136.3 billion (EU25) in 2010 in the EU and are still rising. European health care systems face the challenge of improving access to cost-effective treatments while simultaneously working to sustain budgetary stability in times of economic austerity.

Internet-based depression treatment appears a very promising alternative to current routine depression treatment strategies. Meta-analyses have demonstrated the clinical effectiveness and potential cost-effectiveness of Internet-based treatment for depression in controlled research setting. Internet-based treatment thus has the potential to keep depression treatment affordable, as it enables mental health care providers to reach out to large populations needing depression treatment at a better cost-effectiveness than those of standard treatment as usual (TAU), but with similar levels of clinical efficacy and quality of care. The trials will be conducted in 8 European countries.

Objective

To compare the clinical and cost-effectiveness of blended CBT and TAU in secondary care

Methods

In Switzerland, a randomized-controlled trial will be carried out in secondary care, comparing the clinical and cost-effectiveness of CBT and TAU for adults with major depressive disorder (MDD). Respondents will be followed until 12 months after baseline (measures will be taken at BL, 12 weeks, 18 weeks, 6 months and 12 months).

Study Timeline

• Study Start: 2015-03
• Study First Submitted: 2015-04-02
• Study First Submitted QC: 2015-04-02
• Study First Posted: 2015-04-07
• Primary Completion: 2017-07
• Study Completion: 2017-07
• Status Verified: 2017-09
• Last Update Submitted: 2017-09-20
• Last Update Posted: 2017-09-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Being 18 years of age or older
• Meet DSM-IV diagnostic criteria for MDD confirmed by MINI International Neuropsychiatric Interview version 5.0
• Informed Consent
• Having access to a PC and Internet connection
• Having a Smartphone that is compatible with the mobile component of the intervention
• Understanding of the German language spoken and written

Exclusion Criteria

• Current high risk for suicide according to the MINI Interview section C
• Serious psychiatric co-morbidity: substance dependence, bipolar affective disorder, psychotic illness, obsessive compulsive disorder, as established at the MINI interview
• Currently receiving psychological treatment for depression
• Being unable to comprehend the spoken and written language (German)
• Not having access to a PC and fast Internet connection (i.e. broadband or comparable).
• Not having a Smartphone that is compatible with the mobile component of the intervention that is offered or not willing to carry a Smartphone during the duration of treatment

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Patient Health Questionnaire-9 (PHQ-9)	18 weeks

Secondary Outcome Measures

Name	Time	Method
Assessment of Quality of Life (AQoL-6D)	Baseline, 12 weeks, 18 weeks, 6 months, and 12 months
Quick Inventory of Depressive Symptomatology Self-Report (QIDS-16-SR)	Baseline, 12 weeks, 18 weeks, 6 months, and 12 months
MINI International Neuropsychiatric Interview (M.I.N.I; Ackenheil et al., 1999)	Baseline, 18 weeks, and 12 months
EuroQoL (EQ-5D-5L; Herdman et al., 2011)	Baseline, 12 weeks, 18 weeks, 6 months, and 12 months
Questionnaires on Costs Associated with Psychiatric Illness (TiC-P; Hakkaart-van Rooijen, van Straten, Donker, Tiemens, 2002)	Baseline, 12 weeks, 18 weeks, 6 months, and 12 months
Client Satisfaction Questionnaire (CSQ-8; Nguyen, Attkinson, & Stegner, 1983)	12 weeks, and 18 weeks
System Usability Scale (SUS; Brooke, 1996)	12 weeks, and 18 weeks
Patient Health Questionnaire-9 (PHQ-9)	Baseline, 12 weeks, 6 months, and 12 months

Trial Locations

Locations (2)

Sanatorium Kilchberg; 🇨🇭 Kilchberg, Zurich, Switzerland

Department of Clinical Psychology and Psychotherapy; 🇨🇭 Bern, Switzerland